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Rationale: 
 
The incidence of anal cancer in the general population has increased 
over the last 30 years although it remains a relatively rare entity. A 
number of clinical trials conducted in the 1990’s, showed that 
radiotherapy combined with chemotherapy can cure the disease in the 
majority of patients whilst preserving the anal sphincter. Trials that 
investigated chemotherapy combinations failed to improve over the 
current standard combination of mitomycin-C and 5-FU. However, as 
different radiation strategies and schedules were used in the various 
phase II and phase III trials (that primarily addressed chemotherapy 
questions), we performed a pooled analysis of the data from all 
available phase II and III trials in to identify radiotherapy related 
parameters affecting the outcome of patients with anal cancer, 
resulting in new and improved guidelines for future studies and for 
tailor-made treatment.  
Methods: A total of 13 trials (7 phase II and 6 phase III) conducted 
were identified, totaling 3227 patients recruited between 1986 and 
2010. Data from 3036 patients from 10 studies were received (94.1%). 
Of these studies, 3 were conducted before 1994 and randomized 
against radiation alone or combined with 5FU only. These studies were 
excluded from the main analysis which focuses on radiation combined 
with doublet chemotherapy (N=2033). Patients not ≤75 years, not M0, 
or T1N0 were excluded, as well as all patients treated by 
brachytherapy, those who received <40 Gy of treatment (considered 
unfit) leaving 1343 patients in the analysis. The primary endpoint is 
loco-regional control within 5 years of entry on study. Loco-regional 
failure included events of local or regional failure and the need for 
local surgery. Secondary endpoints were progression-free and overall 
survival. A cox model adjusted by patient and disease factors was 
fitted to study the impact of treatment dose and duration. Statistical 
significance is claimed at the 5% level. 
Results: The radiotherapy regimens used in the studies are described 
in Table 1. 
Two third of the 1342 patients were women; the median age was 56 
years (range: 25-75). Tumor was confined to the anal margin in 82 
patients (6.1%). The median tumor size was 4.1 cm, 64.1% of the 
patients had T. The median follow-up in the studies was 4.1years. By 
year 5, a total of 303 events of loco-regional failure were observed 
with 5-year cumulative incidence of 25.1% (95%CI: 21.9-28.3%). The 
model included effects for sex, age (in years), N stage (N+ inguinal 
nodes -, N+inguinal nodes -, N+ unknown inguinal status vs N0), tumor 
localization (anal canal vs anal margin only), tumor size in cm (within 
combinations of tumor location and N category), total dose on the 
anal canal (≤50.5 Gy vs >50.5-55Gy,  >55-59 G, >59-59.4 Gy,>59.4 Gy) 
and overall treatment time within defined dose. This model shows a 
statistically significant negative impact of tumor size (P=0.0026) and 
of prolonged overall treatment time (P=0.0126). When the overall 
treatment time is split between the duration of the gap and the 
duration of the effective treatment time only the duration of the gap 
remained statistically significant (P=0.0049) whether the effective 
duration of the treatment lost statistical significance (P=0.0786). 
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Notch signaling is a highly conserved short-range cell-cell 
communication pathway that regulates many aspects of embryonic 
development as well as cell renewal and maintenance of adult tissues. 
In humans there are 4 Notch transmembrane receptors that are 
activated by cell surface ligands on adjacent cells of the Delta and 
Jagged families. Upon ligand binding, Notch receptors are cleaved by 
g-secretase, releasing the Notch intracellular domain (NICD) that 
migrates to the nucleus and controls the expression of numerous 
genes.  
Notch is aberrantly expressed in many cancers and both activating as 
well inactivating mutations are found. Notch signaling is not only 
important for cancer cells but also required for tumor angiogenesis. 
Thus, Notch inhibition is an attractive therapeutic target as it could 
target both tumors and their microenvironment simultaneously. Drugs 
that inhibit Notch activation such as g-secretase inhibitors (GSIs) are 
currently in clinical development.  
Here I will present an introduction on the Notch signaling pathway its 
involvement in cancer development and the promises and pitfalls of 
Notch as a drug target for therapeutic intervention in cancer.  
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Risk can be defined as a possibility of harm or damage and this is 
certainly applicable to risk in radiotherapy with potential harm to 
patients or staff associated with so many of our routine procedures.  
Risk is a therefore a fact of life in radiotherapy, it cannot be 
eliminated but it can be minimized by good management.  
Management is defined in the Oxford dictionary as the process of 
dealing with or controlling people or things.  When we link the two 
together then we see that what is important is acknowledging the 
risk, identifying the areas of most significant risk, the factors 
contributing to the risk and continuously considering ways in risk can 
be minimized or eliminated – creating a safety aware culture. 
Risk management in radiotherapy has gained significant momentum in 
recent years partly as a result of the high profile incidents that have 
been reported in the media.  Patients have a right to expect high 
quality treatment delivered in a safe environment.  The negative 
publicity generated by the media articles greatly enhances fear 
amongst the general public and our patient population and we have a 
moral and ethical responsibility to actively address the risks 
associated with our discipline and to create an environment of 
openness and transparency surrounding risk and how it is managed.  
It is important to remember that most errors or incidents are minor 
but reflect a real opportunity for learning and this is the basis of 
voluntary reporting systems.  An inciden treporting system, or safety 
information system, is one way of demonstrating transparency and a 
department that puts safety as a priority and is engaged inactive 
learning.   Voluntary reporting systems exist locally, nationally 
(PRISMA in The Netherlands) and internationally  (ROSIS and the newly 
developed International Atomic Energy Agency SAFRON system). 
Integration of incident and near incident reporting systems have been 
integrated into safety management programmes in many centres.  
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describes the Dutch charter on a safety management system that sets 
out to perform a regular risk inventory, create a system for blame-
free reporting, develop a system for data analysis and to put a system 
in place for implementation of improvements. 
However incident reporting is only one element of risk management 
and should be seen as a tool to facilitate analysis and identify where 
change will be most effective.   A range of methodologies can be used 
to assess and manage risk including Failure Mode and Effects Analysis 
(FMEA), Root Cause Analysis (RCA) Events and Causa lFactors Analysis 
(ECFA) and incident reporting, investigation and analysis.    
Methodologies can be simple or very complex and are applicable in 
different settings but basically involve identifying factors that have 
led or could lead to incidents occurring and considering strategies to 
manage these factors.      
It is also necessary to consider the organization and the environment 
in which radiotherapy is prepared and delivered and the personnel 
involved as these can also contribute to risk. As systems become more 
complex they become less transparent with greater opportunity for 
incidents to occur. Analysis of the functioning of the organization and 
its personnel can be facilitated by regular audit identifying risk areas.  
Risk management should be seen as a proactive process designed to 
improve quality by reducing risk and the number of incidents that 
occur in our departments.    Incident reporting and analysis is of no 
benefit without feedback and involving all appropriate staff in 
addressing the findings and implementing change.  It is the 
responsibility of all professionals involved in the process and is most 
effective when a strong safety culture exists that is is actively 
supported with research and education. Finally risk management 
involves informing patients and the public in a timely and open 
manner to avoid speculation and sensationalism and ensure that 
radiotherapy is seen as an area where risk and its management is 
integral to practice. 
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Purpose/Objective(s): The current era of evidence-based medicine 
demands rigorous analysis and modeling of treatment outcomes data 
to understand treatment efficacy, patient response, and design 
successful future clinical trials. Statistical methods play a pivotal role 
in evidence-based medicine for developing response models from 
biological and clinical data of individualized prognostic or predictive 
outcomes. In this tutorial, we will provide an overview of various 
statistical methods applied in radiotherapy for fitting of 
response/biological models to dosimetric and clinical data in radiation 
oncology.  
Materials/Methods: Outcomes in radiotherapy are characterized by 
models of tumor control probability (TCP) and the surrounding normal 
tissue complication probability (NTCP). These models could be applied 
to optimize and evaluate the quality of different treatment planning 
modalities and are used in designing new radiotherapy clinical trials 
by estimating the expected therapeutic ratio of new protocols. A 
review of basic analytical and data-driven methods will be provided. 
Different statistical methods in both approaches using case studies 
and examples from our work and others in the literature will be 
presented.    
Results:  A step-by-step approach for the development of response 
TCP/NTCP models will be presented. In case of analytical models, 
parameters and outcomes confidence intervals will be assessed. In 
case of data driven-models, issues related to coding of categorical and 
continuous variables, collinearity, parsimony principle, dimensionality 
reduction, and endpoint type would be discussed. Strategies for 
dealing with missing data,imbalance events, overfitting, and model 
generalizability will be highlighted.   
Conclusions: The main goal of this tutorial is to familiarize the 
radiotherapy practitioner with the different statistical methods for 
building and evaluating radiobiological models of a clinical endpoint. 
Different examples of TCP/NTCP model development and their 
application in clinical decision-making will be presented along with 
discussion of various inter-related issues. 
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Real-life optimisation problems commonly have to cope with 
competing, but equally important objectives and therefore do not 
possess a unique, unambiguous solution. In fact, a given solution 
becomes the “optimum” only by a selection process, which is often 
interactive. This selection needs to resort to the same elements that 
make navigation in a foreign city effective: 1) each location should be 
accessible, 2) directions should be available, 3) a destination should 
be reached directly and precisely.  
Accessibility. The term "Pareto fontier" has become known for the set 
of all competing solutions of a dose planning problem. The 
configuration, and even existence of this Pareto frontier is far from 
trivial in the general setting of dose planning, which is why usually 
only fluence distributions or idealized dose distributions (instead of 
deliverable plans) and physical cost functions (instead of dose-volume 
and some biological cost functions) are considered. Under these 
conditions, each point of the Pareto front can be reached by an 
unconstrained dose optimisation with a specific priority weight for 
each cost function. A more direct alternative is to turn all but one 
cost function into constraints and employ constrained optimisation, 
which also remains viable in the more general setting.  
Orientation. A very thorough way of getting oriented is to explore 
every possible direction and see where it leads. In dose optimisation, 
each exploration requires a full dose optimisation and is hence time 
consuming. To work around this, navigation tools have been devised 
that rely on a set of pre-computed dose plans, and much effort has 
been devoted to reducing the number of these computations. An 
alternative within the framework of constrained optimisation is 
sensitivity analysis, which predicts the change in one cost function if 
another one is altered (i.e. the slope of the tangent to the Pareto 
frontier). This does not require pre-computation, but is restricted to 
small changes and hence relies on a good start location. 
Arrival. No amount of information can avoid that the route to the 
final choice is a repeated cycle of getting directions and taking a step, 
especially when the number of competing objectives is large. Later 
steps could partially invalidate previous ones. Therefore, it becomes 
essential to treat already established cost function values as 
constraints. Besides for navigation “on foot”, constrained optimisation 
is also the key to various methods of automated route finding (i.e. 
proper simultaneous optimisation of multiple criteria) like 
lexicographic ordering or constraint prioritization. These methods 
capture the trade-off rules the expert would usually employ, and 
apply these rules in an attempt to perform at least the most obvious 
selection steps unsupervised. 
Although multi-criteria algorithms are built on mathematically 
rigorous formalisms, the concepts derive their value from their 
interactive usability and the users´ preference, and are therefore 
ultimately subjective.  
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Over the last few years, positron emission tomography (PET) has 
proved to convey useful information for treatment planning in 
radiotherapy. Within this framework, the most straightforward way to 
exploit this information is to use PET images to delineate a target 
volume. An abundant literature deals with this problem and many 
automatic or semi-automatic methods have been proposed, ranging 
from uptake thresholds to very complex segmentation algorithms. Yet, 
to date, the problem remains unsolved and few (or no) methods seem 
to succeed in combining accuracy (low bias) and precision (low 
variance across a broad range of observers, tracers, tumor sites, 
target size/shape, and camera models). 
Several impediments cause this slow progress. The first and primary 
one includes all intrinsic, physical limitations of PET cameras. Images 
are blurred (positron annihilations are difficult to locate in wide 
gantries and in attenuating material) and noisy (annihilation counts 
are low). Noise is generally attenuated by smoothing the images even 
more heavily. By essence, blur complicates the segmentation 
problem, as it increases the uncertainty about the location of the 
target edges. Other, secondary causes have a methodological nature 
and result from the first one. Most segmentation methods stem from 
simple or very heuristic models that approximate roughly or even 
ignore the aforementioned effects, leading to inaccurate results. On 
the other hand, more complex methods are hindered by an over-
fitting effect: they perform well on data they have been calibrated or 
tested with but they generalize poorly to other images, other camera 
models, etc. This leads us to the third impediment, which is the 
difficulty of validating the candidate methods on sufficient and 
appropriate data. In particular, robustness and reproducibility depend 
on the availability of a large number of images, covering most of the 
experimental domain, in terms of tumor sites, target sizes and shapes, 
camera models, etc. Each image should also come with a ground truth 
